Currently, the only PSMA-targeted imaging agent approved by the U.S. Food and Drug Administration is 111In-capromab pendetide (ProstaScint), which is approved for SPECT imaging of biopsy-proven PCa localized to the prostatic bed but at high risk for pelvic LNM. The gene discussed is FOLH1; the disease is posterior cortical atrophy.